Figure 1:
Figure 2:
Thyroid function tests of the study population before and after chemotherapy induction_
| Initial | Post-chemo | t | p | |
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||
| T3 | 2.94 ± 0.79 | 3.25 ± 0.80 | 3.73 | 0.001 |
| T4 | 1.35 ± 0.40 | 1.54 ±0.39 | 2.87 | 0.007 |
| TSH | 1.64 ± 1.22 | 1.94 ± 1.09 | 2.17 | 0.035 |
| TRH | 124.40 ± 96.03 | 338.16 ± 167.08 | 7.86 | < 0.001 |
Correlations between initial thyroid function tests and different factors_
| Initial T3 | Initial T4 | Initial TSH | Initial TRH | |||||
|---|---|---|---|---|---|---|---|---|
| r | p | r | p | r | p | r | p | |
| Age | −0.07 | 0.648 | 0.19 | 0.211 | −0.26 | 0.085 | 0.001 | 0.995 |
| Comorbidity | 0.23 | 0.129 | 0.01 | 0.948 | 0.05 | 0.744 | 0.23 | 0.129 |
| TLC | 0.001 | 0.995 | 0.18 | 0.513 | 0.11 | 0.472 | 0.08 | 0.601 |
| Hb | 0.10 | 0.513 | 0.07 | 0.648 | 0.05 | 0.744 | 0.07 | 0.648 |
| Platelets | 0.17 | 0.264 | 0.10 | 0.513 | 0.03 | 0.845 | 0.01 | 0.948 |
| Risk stratification | 0.01 | 0.948 | 0.26 | 0.085 | 0.17 | 0.264 | 0.03 | 0.845 |
| Diagnosis | 0.19 | 0.211 | 0.27 | 0.073 | 0.20 | 0.188 | 0.29 | 0.053 |
| Initial bone marrow aspirate | −0.14 | 0.359 | −0.29 | 0.053 | −0.19 | 0.211 | −0.01 | 0.948 |
| Initial flow | −0.21 | 0.166 | −0.20 | 0.188 | −0.29 | 0.053 | −0.08 | 0.601 |
| Karyotyping | −0.17 | 0.264 | 0.02 | 0.896 | −0.14 | 0.359 | 0.07 | 0.648 |
| Cytogenetics | −0.23 | 0.129 | −0.001 | 0.995 | −0.18 | 0.513 | −0.07 | 0.648 |
| Overall survival | −0.001 | 0.995 | −0.04 | 0.794 | −0.09 | 0.557 | −0.30 | 0.045 |
| Disease status | −0.12 | 0.432 | −0.13 | 0.395 | −0.16 | 0.294 | −0.21 | 0.166 |
| Disease-free survival | −0.04 | 0.794 | −0.01 | 0.948 | −0.33 | 0.027 | −0.30 | 0.045 |
| Post-chemotherapy MRD | −0.16 | 0.294 | −0.10 | 0.513 | −0.17 | 0.264 | −0.11 | 0.472 |
| Post-chemotherapy aspirate | −0.07 | 0.648 | −0.11 | 0.472 | −0.04 | 0.794 | −0.04 | 0.794 |
Post-induction chemotherapy thyroid function tests of patients receiving HCVAD Vs those receiving CALGB_
| HCVAD | CALGB | t | p | |
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||
| T3 | 3.22 ± 0.85 | 3.53 ± 0.52 | 1.11 | 0.054 |
| T4 | 1.59 ± 0.36 | 1.50 ± 0.32 | 0.67 | 0.511 |
| TSH | 1.69 ± 1.19 | 2.31 ± 1.04 | 1.49 | 0.146 |
| TRH | 344.45 ± 178.86 | 317.01 ± 158.93 | 0.42 | 0.674 |
Demographic data of the study population_
| Baseline clinical characteristics | Patient group (N = 44) |
|---|---|
| Age (years), mean (SD), (range) | 29.56 13.91, (15–60) |
| < 39 years | 84% (37/44) |
| > 40 years | 16% (7/44) |
| Gender | |
| Male | 84% (37/44) |
| Female | 16% (7/44) |
| Type of ALL | |
| B-ALL | 77.2% (34/44) |
| T-ALL | 22.7% (10/44) |
| Karyotyping | |
| Normal | 96% (42/44) |
| Abnormal | 4% (2/44) |
| Cytogenetics | |
| Philadelphia chromosome (+) | 18.18% (8/44) |
| Philadelphia chromosome (−) | 77.27% (34/44) |
| Others (7q31/7q22& monosomy 7 negative, Del7q31+11 positive) | 4% (2/44) |
| Comorbidities | |
| NonComorbid (DM, HTN, CKD) | 94% (41/44) |
| 6% (3/44) | |
| Chemotherapy regimen | |
| HCVAD | 57% (25/44) |
| CALGB | 34% (15/44) |
| Total 15 | 5% (2/44) |
| Others | 4% (2/44) |
| Minimal residual disease (MRD) | 0.009 (0.001–0.06) |
| Positive (>0.01 %) | 27% (12/44) |
| Negative (<0.01 %) | 54% (24/44) |
| Not available as patient died in induction | 19% (8/44) |
| Disease status after induction | |
| Remission | 59% (26/44) |
| Relapsed | 22 % (10/44) |
| Patient died during induction | 18% (8/44) |
| 6 months survival rate | |
| Alive | 70% (31/44) |
| Dead | 30% (13/44) |
| Disease-free survival (months),(SD), range | 7.85 (6.46), 2–24 |